Appendix 1—table 8. Antibiotic classes, their contribution to total hospital antibiotic consumption, their spectrum, and their relative rate of inducing microbiome dysbiosis.
Consumption data come from the French ANSM and are supplemented with data from Baggs et al. (Agence nationale de sécurité du médicament et des produits de santé, 2017; Baggs et al., 2016). The literature was used to classify antibiotic classes in terms of their spectrum, (Abbara et al., 2020; Tan et al., 2017) and relative rate of causing microbiome dysbiosis. (Baggs et al., 2018; Brown et al., 2013) The percentage column does not total to 100 due to rounding error.
| Antibiotic class | ACT code | % of consumption | Spectrum | Rate of inducing microbiome dysbiosis |
|---|---|---|---|---|
| Amoxicillin and beta-lactamase inhibitor | J01CR02 | 32.4 | Broad | High |
| Penicillins with extended spectrum | J01CA | 21.9 | Narrow | Medium |
| Quinolones | J01M | 11.0 | Broad | High |
| C3G | J01DD | 8.2 | Broad | Very high |
| C1G | J01DB | 3.7 | Narrow | High |
| Macrolides | J01FA | 3.4 | Narrow | Medium |
| Imidazole | J01XD | 2.9 | Narrow | Medium |
| Piperacillin and beta-lactamase inhibitor | J01CR05 | 2.3 | Broad | High |
| Aminoglycosides | J01G | 2.3 | Narrow | Low |
| Tetracyclines | J01A | 2.0 | Narrow | Low |
| Sulfonamides, trimethoprim | J01E | 1.8 | Narrow | Medium |
| Glycopeptides | J01XA | 1.8 | Narrow | Very high |
| Lincosamides | J01FF | 1.6 | Broad | Very high |
| Carbapenems | J01DH | 1.5 | Broad | High |
| Penicillins (other) | J01C_other | 1.4 | Narrow | Medium |
| C2G | J01DC | 0.9 | Narrow | High |
| C4G | J01DE | 0.6 | Broad | Very high |
| Other | Other | 2.1 | Narrow | Medium |